Patient Input

Patient Input


 

We want as many people as possible living with HIV and hepatitis C to have their voices heard by drug regulators.

 

New drugs are submitted by manufacturers to Health Canada for a Notice of Compliance (NOC). Following the satisfactory review of a submission, an NOC is issued to a manufacturer to signify compliance with Food and Drug Regulations.

 

In a separate process the Canadian Agency for Drugs and Technologies in Health (CADTH) puts out a call to all patient groups to submit input regarding the drug seeking a NOC.

 

CTAC regularly contributes to the CADTH Common Drug Review Patient Input process for a number of HIV and hepatitis C drugs.

 

The experiences and feedback from patients are key in informing the recommendations CADTH makes to publicly funded drug plans throughout Canada.

 

To sign up for notifications about future patient input consultations please email info@ctac.ca.

Previous Patient Input Consultations


 

DOLUTEGRAVIR/LAMIVUDINE (DTG + 3TC)


In February and March 2019 we carried out a patient input consultation about Dolutegravir/Lamivudine (DTG + 3TC),  manufactured by ViiV Healthcare. This new drug to treat HIV-1 infection is a fixed dose combination (single pill), 2-drug regimen.

 

Clinical trial results show the potential for fewer adverse events, as well as improved bone and kidney outcomes, with Dolutegravir + Lamivudine when compared to DTG + Tenofovir/Emtricitabine (TDF/FTC) which is Dolutegravir + Truvada. Find out more here.

 

If you would like to find out more please do get in touch with Amanda Fletcher at amanda@ctac.ca.

 

 

 

 

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR (SOF/VEL/VOX)


This hepatitis C medication is pan-genotypic and has been researched as an option for various patient populations including people living with HIV/HCV co-infection, people with past treatment failure, people living with cirrhosis and people who have had liver or renal transplants. This webinar discussed the clinical trials supporting this new drug’s examination by Canada’s Common Drug Review.

GLECAPREVIR/PIBRENTASVIR (G/P)


This hepatitis C medication is pan-genotypic and has been researched as an option for various patient populations including people living with HIV/HCV co-infection, people with past treatment failure, people living with cirrhosis and people who have had liver or renal transplants